gemcitabine has been researched along with genistein in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Duska, L; He, X; Klein, A; Mallett, A; Roche, M; Seiden, MV; Supko, JG | 1 |
| Abbruzzese, J; Ali, S; Banerjee, S; Bhuiyan, M; Chiao, PJ; Philip, PA; Sarkar, FH; Wang, Z; Zhang, Y | 1 |
| Abbruzzese, J; Ali, IF; Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
| Konduri, S; Schwarz, RE | 1 |
| Feng, J; Liu, B; Shi, ZL; Tao, HM; Yan, XB; Zhang, B | 1 |
| Lai, J; Li, H; Liang, C; Liu, B; Shen, C; Shi, Z; Tao, HM | 1 |
| Berkenstam, A; Dai, B; DiLorenzo, S; Fleming, J; Hases, L; Ibrahim, A; Jafferali, MH; Jose Augustine, J; Kang, Y; Kim, M; Lin, CY; Mesmar, F; Wang, J; Williams, C; Zhao, Y | 1 |
8 other study(ies) available for gemcitabine and genistein
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Complementary Therapies; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Genistein; Glucuronides; Humans; Isoflavones; Middle Aged; Ovarian Neoplasms; Paclitaxel; Soy Milk; Topotecan | 2006 |
Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Female; Gemcitabine; Genistein; Humans; Mice; Mice, Inbred ICR; Mice, Nude; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Random Allocation; Xenograft Model Antitumor Assays | 2005 |
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Genistein; Humans; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
Estrogen receptor beta/alpha ratio predicts response of pancreatic cancer cells to estrogens and phytoestrogens.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Coumestrol; Deoxycytidine; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens, Non-Steroidal; Gemcitabine; Genistein; Humans; In Vitro Techniques; Pancreatic Neoplasms; Predictive Value of Tests; Tamoxifen | 2007 |
Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Genistein; Humans; NF-kappa B; Osteosarcoma; Proto-Oncogene Proteins c-akt | 2010 |
Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-κB pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genistein; Humans; Mice; Mice, Inbred BALB C; NF-kappa B; Osteosarcoma; Proto-Oncogene Proteins c-akt; Signal Transduction | 2012 |
Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Genistein; Humans; Mice; Models, Biological; Mucin-1; Pancreatic Neoplasms; Protein Kinase Inhibitors; Receptors, Estrogen; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |